Novo Nordisk A/S reports a 25% sales increase to DKK 290.4 billion in 2024 and a 26% operating profit growth to DKK 128.3 billion, driven by significant sales in diabetes and obesity care. The company completed the acquisition of three manufacturing sites from Catalent and projects a sales growth of 16-24% for 2025.